Cargando…
Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
BACKGROUND: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer (HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG), submandibular (SMG), and accessory salivary glands represented by the oral ca...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680304/ https://www.ncbi.nlm.nih.gov/pubmed/23721062 http://dx.doi.org/10.1186/1748-717X-8-132 |
_version_ | 1782273100328468480 |
---|---|
author | Chajon, Enrique Lafond, Caroline Louvel, Guillaume Castelli, Joël Williaume, Danièle Henry, Olivier Jégoux, Franck Vauléon, Elodie Manens, Jean-Pierre Le Prisé, Elisabeth de Crevoisier, Renaud |
author_facet | Chajon, Enrique Lafond, Caroline Louvel, Guillaume Castelli, Joël Williaume, Danièle Henry, Olivier Jégoux, Franck Vauléon, Elodie Manens, Jean-Pierre Le Prisé, Elisabeth de Crevoisier, Renaud |
author_sort | Chajon, Enrique |
collection | PubMed |
description | BACKGROUND: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer (HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG), submandibular (SMG), and accessory salivary glands represented by the oral cavity (OC). METHODS: Seventy consecutive patients with Stage I-II (23%) or III/IV (77%) HNC treated by definitive IMRT were included. For all LR failure patients, the FDG-PET and CT scans documenting recurrence were rigidly registered to the initial treatment planning CT. Failure volumes (Vf) were delineated based on clinical, radiological, and histological data. The percentage of Vf covered by 95% of the prescription isodose (Vf-V95) was analyzed. Failures were classified as “in-field” if Vf–V95 ≥ 95%, “marginal” if 20% < Vf-V95 < 95%, and “out-of-field” if Vf-V95 ≤20%. Correlation between Vf-V95 and mean doses (Dmean) in the PG, SMG, and OC was assessed using Spearman’s rank-order correlation test. The salivary gland dose impact on the LR recurrence risk was assessed by Cox analysis. RESULTS: The median follow-up was 20 months (6–35). Contralateral and ipsilateral PGs were spared in 98% and 54% of patients, respectively, and contralateral and ipsilateral SMG in 26% and 7%, respectively. The OC was spared to a dose ≤40 Gy in 26 patients (37%). The 2-year LR control rate was 76.5%. One recurrence was “marginal”, and 12 were “in-field”. No recurrence was observed in vicinity of spared structures. Vf-V95 was not significantly correlated with Dmean in PG, SMG, and OC. The LR recurrence risk was not increased by lower Dmean in the salivary glands, but by T (p = 0.04) and N stages (p = 0.03). CONCLUSION: Over 92% of LR failures occurred “in-field” within the high dose region when using IMRT with a whole salivary gland-sparing strategy. Sparing SMG and OC in addition to PG thus appears a safe strategy. |
format | Online Article Text |
id | pubmed-3680304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36803042013-06-13 Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control Chajon, Enrique Lafond, Caroline Louvel, Guillaume Castelli, Joël Williaume, Danièle Henry, Olivier Jégoux, Franck Vauléon, Elodie Manens, Jean-Pierre Le Prisé, Elisabeth de Crevoisier, Renaud Radiat Oncol Research BACKGROUND: The objective was to analyze locoregional (LR) failure patterns in patients with head-and-neck cancer (HNC) treated using intensity-modulated radiotherapy (IMRT) with whole salivary gland-sparing: parotid (PG), submandibular (SMG), and accessory salivary glands represented by the oral cavity (OC). METHODS: Seventy consecutive patients with Stage I-II (23%) or III/IV (77%) HNC treated by definitive IMRT were included. For all LR failure patients, the FDG-PET and CT scans documenting recurrence were rigidly registered to the initial treatment planning CT. Failure volumes (Vf) were delineated based on clinical, radiological, and histological data. The percentage of Vf covered by 95% of the prescription isodose (Vf-V95) was analyzed. Failures were classified as “in-field” if Vf–V95 ≥ 95%, “marginal” if 20% < Vf-V95 < 95%, and “out-of-field” if Vf-V95 ≤20%. Correlation between Vf-V95 and mean doses (Dmean) in the PG, SMG, and OC was assessed using Spearman’s rank-order correlation test. The salivary gland dose impact on the LR recurrence risk was assessed by Cox analysis. RESULTS: The median follow-up was 20 months (6–35). Contralateral and ipsilateral PGs were spared in 98% and 54% of patients, respectively, and contralateral and ipsilateral SMG in 26% and 7%, respectively. The OC was spared to a dose ≤40 Gy in 26 patients (37%). The 2-year LR control rate was 76.5%. One recurrence was “marginal”, and 12 were “in-field”. No recurrence was observed in vicinity of spared structures. Vf-V95 was not significantly correlated with Dmean in PG, SMG, and OC. The LR recurrence risk was not increased by lower Dmean in the salivary glands, but by T (p = 0.04) and N stages (p = 0.03). CONCLUSION: Over 92% of LR failures occurred “in-field” within the high dose region when using IMRT with a whole salivary gland-sparing strategy. Sparing SMG and OC in addition to PG thus appears a safe strategy. BioMed Central 2013-05-30 /pmc/articles/PMC3680304/ /pubmed/23721062 http://dx.doi.org/10.1186/1748-717X-8-132 Text en Copyright © 2013 Chajon et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Chajon, Enrique Lafond, Caroline Louvel, Guillaume Castelli, Joël Williaume, Danièle Henry, Olivier Jégoux, Franck Vauléon, Elodie Manens, Jean-Pierre Le Prisé, Elisabeth de Crevoisier, Renaud Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
title | Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
title_full | Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
title_fullStr | Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
title_full_unstemmed | Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
title_short | Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
title_sort | salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680304/ https://www.ncbi.nlm.nih.gov/pubmed/23721062 http://dx.doi.org/10.1186/1748-717X-8-132 |
work_keys_str_mv | AT chajonenrique salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT lafondcaroline salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT louvelguillaume salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT castellijoel salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT williaumedaniele salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT henryolivier salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT jegouxfranck salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT vauleonelodie salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT manensjeanpierre salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT lepriseelisabeth salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol AT decrevoisierrenaud salivaryglandsparingotherthanparotidsparingindefinitiveheadandneckintensitymodulatedradiotherapydoesnotseemtojeopardizelocalcontrol |